BioWorld Asia

Sep. 29, 2004

Qiagen Pays $28.5M Cash For Molecular Staging Technology

Qiagen NV is paying $28.5 million in cash to acquire whole-genome amplification technology from Molecular Staging Inc. (BioWorld International) Read More

ExonHit Therapeutics' ALS Drug Fails In Phase III Trial

Cells' Strategy For Rejuvenation Boosts Stem Cell Therapy Hope

France Gives Green Light To Embryonic Stem Cell Imports

Public, Private Sectors At Odds Over German Biotech Direction

Physiomics Enters Deal With Bayer, Eyes IPO On AIM Index

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 30, 2026.

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026